Clinical Trials Browser

INDUSTRY × Interventional × Epoetin Alfa × Clear all

NCT00338286 2018-03-19

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Phase 3 Completed

2,098 enrolled 12 charts

BreastClassical hematology

Anemia, Breast Neoplasms, Neoplasm Metastasis

NCT00711958 2017-09-05

Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients

Phase 3 Completed

114 enrolled 10 charts

Classical hematology

Anemia

NCT00495378 2016-12-20

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

Phase 4 Terminated

Classical hematology

Anemia, Neoplasms

NCT01374373 2016-04-07

Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia

Phase 4 Completed

Classical hematology

Anemia

NCT00267007 2014-06-04

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Phase 2 Terminated

32 enrolled 9 charts

Neoplasms, Peripheral Nervous System Diseases

NCT00386152 2013-07-19

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Phase 2 Terminated

235 enrolled 13 charts

Classical hematology

Anemia, Neoplasms

NCT00148421 2013-05-15

Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.

Phase 3 Completed

Classical hematology

Anemia

NCT01394991 2012-04-05

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

Phase 4 Completed

504 enrolled 17 charts

Classical hematology

Anemia, Neoplasms

NCT00036400 2011-06-10

Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

Phase 3 Completed

Classical hematologyGastrointestinal

Anemia, Rectal Neoplasms, Stomach Neoplasms

NCT00210587 2011-06-10

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Phase 3 Completed

Classical hematology

Anemia, Neoplasms

NCT00210600 2011-06-10

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Phase 2 Completed

Classical hematology

Anemia

NCT00210730 2011-06-10

The Duration Study

Phase 3 Terminated

Classical hematology

Anemia, Neoplasms

NCT00210834 2011-06-10

An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Phase 2 Completed

Classical hematology

Anemia

NCT00337948 2011-06-10

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00338416 2011-06-10

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00341055 2011-06-10

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

Phase 3 Completed

Classical hematology

Anemia, Neoplasms

NCT00269984 2011-06-08

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00261677 2011-05-23

A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy

Phase 3 Completed

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00338299 2011-05-23

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

Phase 2 Completed

Classical hematology

Anemia

NCT00216541 2011-05-19

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Phase 4 Completed

Classical hematology

Anemia, Neoplasms

NCT00246597 2011-05-19

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

Phase 3 Terminated

BreastClassical hematology

Anemia, Breast Neoplasms, Red-Cell Aplasia, Pure

NCT00315484 2011-05-19

Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia

Phase 4 Completed

Classical hematology

Anemia

NCT00350090 2011-05-19

A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

Phase 3 Terminated

Classical hematology

Anemia, Neoplasms

NCT00266617 2011-05-18

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00269997 2011-05-18

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00270049 2011-05-18

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Phase 2 Completed

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Leukemia, Lymphoid, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00270101 2011-05-18

The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma

Phase 3 Completed

Classical hematologyPlasma cell

Anemia, Multiple Myeloma, Neoplasms

NCT00270127 2011-05-18

Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy

Phase 3 Completed

Classical hematology

Anemia, Neoplasms

NCT00270166 2011-05-18

The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy

Phase 3 Completed

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicLymphoidPlasma cellThoracic

Anemia, Breast Neoplasms, Esophageal Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT00306267 2011-05-18

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Phase 2 Terminated

Classical hematology

Anemia, Neoplasms

NCT00388336 2011-05-18

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00083434 2011-04-27

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Phase 3 Terminated

Classical hematology

Anemia, Neoplasms

NCT00083486 2011-04-27

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Phase 3 Terminated

Classical hematology

Anemia

NCT00283465 2011-01-14

A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

Phase 4 Completed

Classical hematology

Anemia, Neoplasms

NCT00211133 2010-11-30

A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy

Phase 3 Completed

BreastClassical hematology

Anemia, Breast Neoplasms

NCT00364455 2010-04-27

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Phase 3 Completed

Classical hematology

Anemia, Carcinoma

NCT00524407 2010-04-02

Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy

Phase 4 Completed

Classical hematology

Anemia, Neoplasms